<DOC>
	<DOC>NCT00702143</DOC>
	<brief_summary>Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).</brief_summary>
	<brief_title>A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Inclusion Criteria AD: Male or female &gt;=50 years of age Meet National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS) criteria for probable AD with MMSE score of 1024 Inclusion Criteria MCI: Male or female &gt;=50 years of age Have a Clinical Dementia Rating (CDR) of 0.5 MMSE &gt;24 Normal subjects: Male or female &gt;=50 years of age MMSE &gt;=29 Normal on psychometric test battery at screening Provide informed consent Have a history or current diagnosis of other neurologic disease Have had or currently have a diagnosis of other neurodegenerative disease Have participated in experimental therapy targeted to amyloid plaque</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>